Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Lonza plans to invest approximately CHF 500 million to upgrade the facility
A five-day inspection was concluded successfully with no critical and no major observations raised
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
The investment will catalyse various components of the IndiaAI Mission
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
Acquisition of exclusive commercialization rights for European markets
Subscribe To Our Newsletter & Stay Updated
